Influenza immunology evaluation and correlates of protection: a focus on vaccines

Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine

(2016) Patricia Izurieta et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Current and next generation influenza vaccines: Formulation and production strategies

(2015) Peter C. Soema et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Flucelvax (Optaflu) for seasonal influenza

(2015) Ilaria Manini et al.   Expert Review of Vaccines

Validation of Single Radial Haemolysis assay: A reliable method to measure antibodies against influenza viruses

(2015) Claudia Maria Trombetta et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection

(2015) Arnold S. Monto et al.   JOURNAL OF INFECTIOUS DISEASES

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

(2015) Hadi M Yassine et al.   NATURE MEDICINE

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

(2015) A. Impagliazzo et al.   SCIENCE

Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age

(2015) Markus Knuf et al.   VACCINE

Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children

(2015) Åke Örtqvist et al.   VACCINE

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

(2015) José Garcia-Sicilia et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

(2015) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses

(2015) Peter Christiaan Soema et al.   Frontiers in Immunology

Pseudotype-Based Neutralization Assays for Influenza: A Systematic Analysis

(2015) George William Carnell et al.   Frontiers in Immunology

Microneutralization Assay Titres Correlate with Protection against Seasonal Influenza H1N1 and H3N2 in Children

(2015) Chris P. Verschoor et al.   PLoS One

Heterologous Prime-Boost Vaccination Using an AS03B-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children

(2014) Terry Nolan et al.   JOURNAL OF INFECTIOUS DISEASES

Association Between Antibody Titers and Protection Against Influenza Virus Infection Within Households

(2014) Tim K. Tsang et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age

(2014) Markus Knuf et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

(2014) Paul Gillard et al.   Trials

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

(2014) Terry Nolan et al.   VACCINE

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

(2014) Juan Carlos Tinoco et al.   VACCINE

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

(2014) Sharon E. Frey et al.   VACCINE

Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

(2014) Cécile van Els et al.   Human Vaccines & Immunotherapeutics

A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination

(2014) Keith S Reisinger et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial

(2014) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

(2013) Jiří Beran et al.   BMC INFECTIOUS DISEASES

Immunological assessment of influenza vaccines and immune correlates of protection

(2013) Adrian Reber et al.   Expert Review of Vaccines

Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase

(2013) Robert B. Couch et al.   JOURNAL OF INFECTIOUS DISEASES

Neuraminidase-Inhibiting Antibody Is a Correlate of Cross-Protection against Lethal H5N1 Influenza Virus in Ferrets Immunized with Seasonal Influenza Vaccine

(2013) S. Rockman et al.   JOURNAL OF VIROLOGY

Cellular immune correlates of protection against symptomatic pandemic influenza

(2013) Saranya Sridhar et al.   NATURE MEDICINE

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

(2012) Laurent Coudeville et al.   BMC Medical Research Methodology

Nomenclature for Immune Correlates of Protection After Vaccination

(2012) S. A. Plotkin et al.   CLINICAL INFECTIOUS DISEASES

The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets

(2012) Zhongying Chen et al.   VACCINE

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming

(2012) Maikel V.W. van der Velden et al.   VACCINE

Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines—An effective EU regulatory approach

(2012) Ralf Wagner et al.   VACCINE

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

(2012) David P. Greenberg et al.   VACCINE

Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice

(2012) Judith D. Easterbrook et al.   VIROLOGY

Correlates of vaccine protection from influenza and its complications

(2012) Jonathan A. McCullers et al.   Human Vaccines & Immunotherapeutics

Serologic assays for influenza surveillance, diagnosis and vaccine evaluation

(2011) Jacqueline M Katz et al.   Expert Review of Anti-Infective Therapy

A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes

(2011) Laurent Coudeville et al.   Human vaccines & immunotherapeutics

Sensitivity and Specificity of Serologic Assays for Detection of Human Infection with 2009 Pandemic H1N1 Virus in U.S. Populations

(2011) Vic Veguilla et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Population exposure to a novel influenza A virus over three waves of infection

(2011) W.E. Adamson et al.   JOURNAL OF CLINICAL VIROLOGY

Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection

(2011) Suzanne E. Ohmit et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy Studies of Influenza Vaccines: Effect of End Points Used and Characteristics of Vaccine Failures

(2011) Joshua G. Petrie et al.   JOURNAL OF INFECTIOUS DISEASES

A Vero Cell–Derived Whole-Virus H5N1 Vaccine Effectively Induces Neuraminidase-Inhibiting Antibodies

(2011) Richard Fritz et al.   JOURNAL OF INFECTIOUS DISEASES

Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children

(2011) Daniel F. Hoft et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

(2011) P Noel Barrett et al.   LANCET

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

(2011) Steven Black et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Towards universal influenza vaccines?

(2011) A. Osterhaus et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

H5N1 Whole-Virus Vaccine Induces Neutralizing Antibodies in Humans Which Are Protective in a Mouse Passive Transfer Model

(2011) M. Keith Howard et al.   PLoS One

Registration of influenza vaccines for children in Europe

(2011) Marta Granström et al.   VACCINE

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

(2011) Rebecca J. Cox et al.   VACCINE

Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults

(2011) Hana Hakim et al.   VACCINE

Influenza vaccine responses in older adults

(2010) Janet E. McElhaney   AGEING RESEARCH REVIEWS

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine

(2010) David Onions et al.   BIOLOGICALS

Human influenza vaccines and assessment of immunogenicity

(2010) Zichria Zakay-Rones   Expert Review of Vaccines

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study

(2010) Elizabeth Miller et al.   LANCET

Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?

(2010) Regina Allwinn et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

The Efficacy of Live Attenuated and Inactivated Influenza Vaccines in Children as a Function of Time Postvaccination

(2010) Christopher S. Ambrose et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Specific Recognition of Influenza A/H1N1/2009 Antibodies in Human Serum: A Simple Virus-Free ELISA Method

(2010) Mario M. Alvarez et al.   PLoS One

Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to

(2010) Chi-Eun Oh et al.   VACCINE

Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure

(2009) D. L. Noah et al.   Clinical and Vaccine Immunology

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Vaccines: Correlates of Vaccine‐Induced Immunity

(2008) Stanley A. Plotkin   CLINICAL INFECTIOUS DISEASES

Testing human sera for antibodies against avian influenza viruses: Horse RBC hemagglutination inhibition vs. microneutralization assays

(2008) Ghazi Kayali et al.   JOURNAL OF CLINICAL VIROLOGY

Cross-Recognition of Avian H5N1 Influenza Virus by Human Cytotoxic T-Lymphocyte Populations Directed to Human Influenza A Virus

(2008) J. H. C. M. Kreijtz et al.   JOURNAL OF VIROLOGY

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

(2008) Hartmut J. Ehrlich et al.   NEW ENGLAND JOURNAL OF MEDICINE